Interferon alpha for the adjuvant treatment of melanoma: Review of international literature and practical recommendations from an expert panel on the use of interferon

Paolo A. Ascierto, Vanna Chiarion-Sileni, Antonio Muggiano, Mario Mandalà, Nicola Pimpinelli, Michele Del Vecchio, Gaetana Rinaldi, Ester Simeone, Paola Queirolo

Research output: Contribution to journalArticle

Abstract

The degree to which interferon (IFN) alpha-2b offers real clinical benefits in the adjuvant therapy of melanoma at high risk of recurrence is a subject of debate. This, together with questions over optimal treatment scheme and concerns over toxicity, has limited its clinical use. On the basis of a review of the literature, an Italian Expert Panel has made practical recommendations for a consistent approach in the use of IFN. Although it is clear that more research into predictive factors to identify patients most likely to benefit from adjuvant IFN therapy is required, IFN remains the only currently available adjuvant option for melanoma. Based on meta-analyses of clinical trials, there is clear evidence that treatment with IFN is beneficial with regard to overall and recurrence-free survival (RFS). As such, IFN should be offered to patients who are at high risk of recurrence. Specific recommendations with regard to disease stage are provided.

Original languageEnglish
Pages (from-to)193-201
Number of pages9
JournalJournal of Chemotherapy
Volume26
Issue number4
DOIs
Publication statusPublished - 2014

Keywords

  • Adjuvant therapy
  • Interferon alpha-2b
  • Melanoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Interferon alpha for the adjuvant treatment of melanoma: Review of international literature and practical recommendations from an expert panel on the use of interferon'. Together they form a unique fingerprint.

  • Cite this